Daily Turnover | The turnover of Icon on 9/15 was $186.12 Million, Ranking 573

The turnover of Icon on 9/15/2025 was $186.12 million, ranking 573 in today's market, the Volume is 1.08 million.

Icon(ICLR) shares closed at $170.46, down 2.59% on 9/15/2025, down 4.13% in the last 5 trading days, down 4.20% this month, down 18.72% year-to-date and down 42.33% in the last 52 weeks.
*If the company has been listed for less than 52 weeks, the 52-week gain is the gain since the listing.
(The same applies for less than 1 month, or less than 5 trading days)

【History Turnover】

Date	Turnover	Volume	Price	Performance
9/15/2025	$186.12 million	1.08 million	$170.46	-2.59%
9/12/2025	$279.37 million	1.60 million	$175	-0.06%
9/11/2025	$243.50 million	1.41 million	$175.11	5.85%
9/10/2025	$245.44 million	1.47 million	$165.44	-2.07%
9/9/2025	$196.95 million	1.16 million	$168.94	-4.99%

【Company Profile】
Icon Public Limited Company is a contract research organization (“CRO”), providing outsourced development services on a global basis to the pharmaceutical, biotechnology and medical device industries. The company specializes in the strategic development, management and analysis of programs that support all stages of the clinical development process - from compound selection to Phase I-IV clinical studies. The company began operations in 1990. The CRO industry provides independent product development services for the pharmaceutical, biotechnology and medical device industries. Companies in these industries outsource product development services to CROs in order to manage the drug development process more efficiently and to cost-effectively maximize the profit potential of both patent-protected and generic products. The CRO industry has evolved since the 1970s from a small number of companies that provided limited clinical services to a larger number of CROs that offer a range of services that encompass the entire research and development process, including pre-clinical development, clinical trials management, clinical data management, study design, biostatistical analysis, post marketing surveillance, regulatory affairs services and central laboratory services. CROs are required to provide these services in accordance with good clinical and laboratory practices, as governed by the applicable regulatory authorities.